Cargando…

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α

The incidence and prevalence of inflammatory bowel diseases (IBDs) are rapidly increasing worldwide. IBDs are considered an emerging problem not only in Western countries but also in developing counties. The relapses and complications of active IBD mandate various medications. Nevertheless, hospital...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jihye, Cheon, Jae Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Internal Medicine 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449200/ https://www.ncbi.nlm.nih.gov/pubmed/35882566 http://dx.doi.org/10.3904/kjim.2022.132

Ejemplares similares

Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice
por: Ben-Horin, Shomron, et al.
Publicado: (2017)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis
por: Siebenhüner, Alexander R., et al.
Publicado: (2021)

Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease
por: Stallhofer, Johannes, et al.
Publicado: (2023)

Incidence and Prevalence of Inflammatory Bowel Disease across Asia
por: Park, Jihye, et al.
Publicado: (2021)

Anti-inflammatory and pro-anabolic effects of 5-aminosalicylic acid on human inflammatory osteoarthritis models
por: Li, Kaihu, et al.
Publicado: (2022)

Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases
por: Park, Yong Eun, et al.
Publicado: (2022)

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
por: Sood, Ajit, et al.
Publicado: (2020)

Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug
por: Perrotta, Cristiana, et al.
Publicado: (2015)

Cholinergic immunomodulation in inflammatory bowel diseases
por: Serafini, Michele A., et al.
Publicado: (2021)

5-Aminosalicylic Acid Loaded Chitosan-Carrageenan Hydrogel Beads with Potential Application for the Treatment of Inflammatory Bowel Disease
por: Stavarache, Cristina Elena, et al.
Publicado: (2021)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014)

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
por: Strobel, Thomas, et al.
Publicado: (2020)

Therapeutic Efficacy of the Combination Therapy of Corticosteroids and 5-Aminosalicylic Acid for Treatment of Pyoderma Gangrenosum with Ulcerative Colitis
por: Chen, Wei, et al.
Publicado: (2020)

Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
por: Kang, Eun Ae, et al.
Publicado: (2022)

Ulcerative Colitis Impairs the Acylethanolamide-Based Anti-Inflammatory System Reversal by 5-Aminosalicylic Acid and Glucocorticoids
por: Suárez, Juan, et al.
Publicado: (2012)

Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
por: Zhang, Cui, et al.
Publicado: (2018)

Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review
por: Mihai, Ioana Ruxandra, et al.
Publicado: (2023)

Inflammatory Bowel Disease: How Effective Is TNF-α Suppression?
por: Lo, Wing-Cheong, et al.
Publicado: (2016)

Concomitant 5-aminosalicylic acid treatment does not affect 6-thioguanine nucleotide levels in patients with inflammatory bowel disease on thiopurines
por: Looser, Rahel, et al.
Publicado: (2023)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
por: Schultheiss, Johannes P. D., et al.
Publicado: (2021)

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2019)

Correction: Inflammatory Bowel Disease: How Effective Is TNF-α Suppression?
Publicado: (2017)

Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis
por: Qiu, Xinyun, et al.
Publicado: (2016)

Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
por: Amini Kadijani, Azade, et al.
Publicado: (2017)

5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-Analysis
por: Zhao, Li-Na, et al.
Publicado: (2014)

Polymorphisms in PRKCDBP, a Transcriptional Target of TNF-α, Are Associated With Inflammatory Bowel Disease in Korean
por: Kim, Jung-Wook, et al.
Publicado: (2015)

Microbial Modulation in Inflammatory Bowel Diseases
por: Yu, Jongwook, et al.
Publicado: (2022)

Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease
por: Louis, Edouard
Publicado: (2020)

Para-Aminosalicylic Acid: Pas
Publicado: (1950)

FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFα Agents
por: Guidi, Luisa, et al.
Publicado: (2013)

Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
por: Park, Jihye, et al.
Publicado: (2017)

Erratum: Transmembrane TNF-α Density, But Not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
por: Amini Kadijani, Azade, et al.
Publicado: (2017)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Absence of Oral Opportunistic Infections in Patients with Inflammatory Bowel Disease Receiving Anti-TNF-α and Anti-Integrin-α(4)β(7) Therapy
por: Saltović, Ema, et al.
Publicado: (2022)

Differential Effects of Anti-TNFα and Anti-α4β7 Drugs on Circulating Dendritic Cells Migratory Capacity in Inflammatory Bowel Disease
por: Soleto, Irene, et al.
Publicado: (2022)

Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management
por: Park, Jihye, et al.
Publicado: (2021)

Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system
por: How Shing Koy, Elsa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eqh1bbs1fg25bj6m4r9d8ujfi5